On January 31, 2022, it was announced that Exopharm Limited (ASX:EX1), headquartered in Melbourne, Australia, has signed a Master Collaborative Services Agreement (MSA) with the Astellas Institute for Regenerative Medicine (AIRM). AIRM is a US-based subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company headquartered in Tokyo, Japan, with global sales of approximately US $12 billion per annum and strong investment in R&D to support the development of new treatments to address unmet medical needs. "Astellas is keen to evaluate whether exosomes could become part of their future pipeline of innovative products. This collaboration services agreement defines how Astellas and Exopharm will work together in some important initial laboratory work," said Dr. Ian Dixon, Managing Director and Founder of Exopharm.
Exopharm and Astellas Institute for Regenerative Medicine (AIRM) Sign Master Collaborative Services Agreement with Exosome Focus
Login Or Register To Read Full Story